Care Access - Tampa

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Obesity7 trials
• Type 2 diabetes6 trials
• Alzheimer disease3 trials
• Chronic kidney disease2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• Type 1 diabetes1 trial

Phase

• Phase 310 trials

Status

• Active, not recruiting7 trials
• Completed1 trial
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company10 trials

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Eli Lilly and Company· Source

  Contact: Shital Mehta (principal investigator)

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Eli Lilly and Company· Source

  Contact: Brad Lipson (principal investigator)

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

  NCT07035093· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT06972472· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

  NCT06972459· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

  NCT06993792· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source